Floatz logo

Itraconazole

Androgen-insensitive Prostate Cancer

PfizerPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Androgen-insensitive Prostate Cancer cohort.

Asset / SponsorPhaseRating
Casodex
OHSU Knight Cancer Institute
Phase 1/2CCC
Temsirolimus
Sandy Srinivas
Phase 1/2CCC
Mva-Bn-Pro
Bavarian Nordic
Phase 1CC

Same molecule, other indications

Itraconazole is also rated in:

retinoblastomaDormant
BB
Indicative ·
68 / 100
View asset →
fungal infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →
Wilms tumorDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →